Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative <i>All of Us</i> Research Program.

J Clin Med · 2023 · PMC9966763 · PMID 36836203

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

The recently reported RESPECT-EPA trial [ 19 ], while of borderline significance for the primary endpoint, did achieve the secondary endpoint, with relative risk reductions due to icosapent ethyl therapy consistent with REDUCE-IT.

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative &lt;i&gt;All of Us&lt;/i&gt; Research Program.

The sentences

Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative <i>All of Us</i> Research Program.